EANS-Adhoc: AGENNIX AG / Agennix AG Sets Subscription Price at EUR 3.81 per Share for Capital Increase and Subscription Period Planned to Begin on September 17, 2010 -Dievini Hopp BioTech holding P

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Capital Increase; Supscription Price

15.09.2010

Planegg/Munich (Germany), September 15, 2010 - Agennix AG (Frankfurt
Stock Exchange (Prime Standard): AGX/ISIN DE000A1A6XX4) today
announced that its Management Board has resolved, with the approval
of the Supervisory Board, to set the subscription price for a rights
offering and related private placement of unsubscribed shares at EUR
3.81 per share, which represents approximately a 10% discount to the
September 14, 2010 XETRA closing price of EUR 4.23 per Agennix AG
share on the Frankfurt Stock Exchange.

Agennix's Management Board and Supervisory Board have made their
decision on the basis of the authorization granted to them by the
Company's annual general meeting on May 25, 2010 to increase the
Company's share capital by up to 20,588,705 new shares. The Company
is offering up to 20,588,705 newly issued shares in a rights offering
to existing shareholders entitled to participate in the rights
offering at a subscription ratio of 1:1. Shares are being offered in
a public offering in Germany and the Grand Duchy of Luxembourg.
Shares not subscribed in the rights offering will be offered in
private placements to institutional investors outside those two
countries.

In support of the planned capital increase, dievini Hopp BioTech
holding GmbH & Co. KG (dievini), a major shareholder of Agennix AG,
has entered into a firm commitment agreement with the Joint Global
Coordinators, Piper Jaffray Ltd. and WestLB AG, under which dievini
will exercise all its subscription rights with respect to existing
shares held by it and will purchase new shares not subscribed by the
other existing shareholders or which are not placed with new
investors as part of the private placement. Dievini has committed to
invest up to EUR 80 million.

Dievini has informed the Company that it has applied on behalf of
itself, Dietmar Hopp and other persons and legal entities whose
ownership of shares is attributed to Dietmar Hopp to the German
Federal Financial Supervisory Authority (Bundesanstalt fuer
Finanzdienstleistungsaufsicht) (BaFin) for the granting of an
exemption from the obligation to make a mandatory tender offer in
case it acquires new shares pursuant to the firm commitment agreement
or new shares are attributed to dievini pursuant to Section 30 of the
German Takeover Act and dievini thereby acquires control of the
Company in the meaning of Section29 (2) of the German Takeover Act.
The likelihood of receiving such exemption as well as the timing of
any such decision by BaFin remains uncertain.

Furthermore, dievini and certain shareholders deriving their
ownership from Gordon A. Cain, a co-founder of Agennix Incorporated
(the Cain Shareholders), have agreed that, subject to certain limited
exceptions, they will not, during a period ending six months after
the first trading of the new shares, sell any share of the Company or
enter into any transaction or perform any action with equivalent
economic effect.

The Cain Shareholders, which together hold approximately 23% of the
Company's shares, have also entered into an agreement pursuant to
which each Cain Shareholder has undertaken not to exercise its
subscription rights and upon request will transfer its subscription
rights free of charge to parties identified by the banks implementing
the capital increase.

The offer and subscription price for the transaction will be EUR 3.81
per share. The subscription period is expected to begin on September
17, 2010 and end on September 30, 2010. The new shares are expected
to start trading on the Frankfurt Stock Exchange on or about October
5, 2010.

The prospectus for this offering is expected to be approved by the
BaFin on September 15, 2010 and will be available on the Company's
website, {www.agennix.com}[HYPERLINK: http://www.agennix.com], and in
hard copy from Agennix AG, Fraunhoferstrasse 20, 82152 Planegg,
Germany, as well as at the offices of the Joint Global Coordinators,
Piper Jaffray Ltd., One South Place, London EC2M 2RB, United Kingdom
and WestLB AG, Herzogstrasse 15, 40217 Duesseldorf, Germany.

END OF AD HOC ANNOUNCEMENT

About Agennix

Agennix AG is a publicly listed biopharmaceutical company that is
focused on the development of novel therapies that have the potential
to substantially improve the length and quality of life of critically
ill patients in areas of major unmet medical need. The Company's most
advanced program is talactoferrin, an oral therapy that has
demonstrated activity in randomized, double-blind, placebo-controlled
Phase II studies in non-small cell lung cancer, as well as in severe
sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program
further for the treatment of severe sepsis. Other clinical
development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing; the oral platinum-based compound
satraplatin; and a topical gel form of talactoferrin for diabetic
foot ulcers. Agennix's registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany;
Princeton, New Jersey and Houston, Texas. For additional information,
please visit the Agennix Web site at {www.agennix.com}[HYPERLINK:
http://www.agennix.com].

This ad hoc announcement contains forward-looking statements, which
express the current beliefs and expectations of the management of
Agennix AG. Such statements are based on current expectations and are
subject to risks and uncertainties, many of which are beyond our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or implied by such forward-looking statements. Actual
results could differ materially depending on a number of factors, and
we caution investors not to place undue reliance on the
forward-looking statements contained in this ad hoc announcement.
Forward-looking statements speak only as of the date on which they
are made and Agennix undertakes no obligation to update these
forward-looking statements, even if new information becomes available
in the future.

This ad hoc announcement is not for distribution, directly or
indirectly, in or into the United States (including its territories
and possessions, any State of the United States and the District of
Columbia). These materials do not constitute or form a part of any
offer or solicitation to purchase or subscribe for securities in the
United States of America. The shares in Agennix AG (the "Shares")
mentioned herein may not be offered or sold in the United States
absent registration or an exemption from registration under the U.S.
Securities Act of 1933, as amended (the "Securities Act").

The Shares have not been, and will not be, registered under the
Securities Act and will not be offered or sold in the United States,
except on the basis of applicable exemptions from registration. There
will be no public offering of securities in the United States.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: AGENNIX AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Agennix AG

Investor Relations

& Corporate Communications

Phone: +49 (0)89 8565 2693

ir@agennix.com

In the U.S.: Laurie Doyle

Director, Investor Relations

& Corporate Communications

Phone: +1 609 524 5884

laurie.doyle@agennix.com

Additional media contact for Europe:

MC Services AG

Raimund Gabriel

Phone: +49 (0) 89 210 228 0

raimund.gabriel@mc-services.eu

Additional investor contact for Europe:

Trout International LLC

Lauren Williams, Vice President

Phone: +44 207 936 9325

lwilliams@troutgroup.com

Branche: Pharmaceuticals
ISIN: DE000A1A6XX4
WKN: A1A6XX
Index: CDAX, Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Düsseldorf / free trade
Hannover / free trade
München / free trade